Answers are grounded in this paper and cite their sources.
Precision oncology still faces low clinical translation rates. This is largely because two-dimensional (2D) culture systems cannot reproduce tumor heterogeneity and microenvironmental stress. Here, we review the applications of 3D cancer models, including scaffold-free spheroids, patient-derived organoids (PDOs) biobanks, and microphysiological systems (MPSs), in drug resistance modeling and personalized therapy. These platforms effectively model metabolic gradients, lineage plasticity, and immunological features within the tumor microenvironment (TME), thereby bridging the genotype-phenotype gap. They also capture physical immune exclusion, T cell exhaustion, and antigen presentation to facilitate the evaluation of immunotherapies. Last, we discuss key translational bottlenecks such as standardization and throughput, proposing the integration of advanced biomanufacturing, artificial intelligence (AI)–driven phenomics, and computational modeling to develop 3D cancer platforms into clinical predictive systems for optimizing precision treatment strategies.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: